¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Malignant neoplasm without specification of site"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® neoplasm ÇÑ±Û ½Å»ý¹°
¼³¸í   
  »õ·Î »ý±ä ¹°ÁúÀ̶ó´Â ¶æÀÌ´Ù. À̰ÍÀº ´Ù¸¥ ¸»·Î ¡°Á¾¾ç(tumor)¡±À̶ó°íµµ Çϴ µ¥, ½ÇÁ¦·Î À̵éÀÇ ¸íÈ®ÇÑ ¶æÀº ¼­·Î ´Ù¸£´Ù. Á¾¾çÀ̶ó´Â ¸»Àº ¡°±× Å©±â°¡ 1cm°¡ ³Ñ´Â ÀÏÁ¾ÀǠȤ¡±À» ¸»Çϴ °ÍÀ¸·Î ÇǺΰú¿¡¼­´Â À̺¸´Ù ÀÛÀº È¤À» ±¸ÁøÀ̶ó°í ÇÏ¿© ±¸º°ÇÏ¿© ºÎ¸¥´Ù. ÇÏÁö¸¸, À̰ÍÀº ¶ÇÇÑ ÇǺλӸ¸ ¾Æ´Ï¶ó ½Åü³» ¾îµð¿¡¼­µç »ý±æ ¼ö ÀÖÀ¸¹Ç·Î ¸ðµÎ ÅëĪÇÏ¿© Á¾¾çÀ̶ó°í ºÎ¸¥´Ù. ÀÌ¿¡ ºñÇØ ¡°½Å»ý¹°¡±Àº ½Åü³» ¾ø´ø °ÍÀÌ »õ·Î »ý°Ü³µ´Ù´Â ¶æÀ¸·Î ºÙÀΠ¸»ÀÌ´Ù. ±×·¯³ª, ÀÌ µÑÀÇ °ü°è¸¦ ¸íÈ®È÷ ±ÔÁ¤ÁþÁö ¾Ê°í ÀÖÀ¸¸ç ´ë°³ °°Àº ¶æÀ¸·Î È¥¿ëµÈ´Ù.
  
  ½Å»ý¹°¿¡´Â ¡°¾ç¼º(benign)¡±°ú ¡°¾Ç¼º(malignant)¡±ÀÌ ÀÖ´Ù. ÀÌ µÑÀÇ ±¸º°Àº ¿©·¯ °¡Áö ±âÁØ¿¡ µû¸£Áö¸¸, ¶§·Î´Â ±¸º°ÀÌ ¾î·Á¿ï ¶§µµ ÀÖ´Ù. ´ë°³ ¾ç¼ºÀº »ý¸í´ÜÃàÀ» Àß ÀÏÀ¸Å°Áö ¾Ê´Â °ÍÀ¸·Î Ä¡·áÈÄ¿¡ Àç¹ßµµ Àß ÇÏÁö ¾Ê´Â´Ù. ÀÌ¿¡ ºñÇØ ¾Ç¼ºÀº Àç¹ß»Ó¸¸ ¾Æ´Ï¶ó ´Ù¸¥ ±â°üÀ¸·Î ¿Å°Ü°¡¼­ °°Àº º´º¯ÀÌ ¹ß»ýÇϴ ¡°ÀüÀÌ(metastasis)¡±Çö»óµµ ÀϾ´Ù. µû¶ó¼­ »ý¸íÀ» ´ÜÃà½Ã۴ °æ¿ì°¡ ¸¹À¸¸ç, ´ë°³ Ä¡·á°¡ ¾î·Æ´Ù.
¿µ¹® malignant tumor ÇÑ±Û ¾Ç¼ºÁ¾¾ç
¼³¸í   
  Á¤»óÀûÀΠÁ¶Á÷ ¼¼Æ÷°¡ °¢Á¾ ¹°¸®Àû-È­ÇÐÀû-»ý¹°ÇÐÀûÀΠ¹ß¾Ï ¹°ÁúÀÇ Àۿ렶Ǵ ¿äÀο¡ ÀÇÇØ µ¹¿¬º¯À̸¦ ÀÏÀ¸ÄѼ­ Çü¼ºµÇ´Â Á¾¾ç. ¹«Á¦ÇÑÀÇ ¼¼Æ÷ºÐ¿­·Î ¸Å¿ì ¿Õ¼ºÇϰԠÁõ½ÄÇÏ¿© ÁÖÀ§Á¶Á÷À» ÆÄ±«-ħ½ÄÇÑ´Ù. ¶Ç ¾î¶² È­Çй°ÁúÀ» ³»¾î ÁÖÀ§ÀÇ Á¶Á÷¼¼Æ÷¸¦ Ä§ÇØÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ¹× ¸²ÇÁ°üÀ» µû¶ó ÀüÀÌÇÏ¿© Àü½ÅÀÇ Ä«ÄʽþƸ¦ÀÏÀ¸ÄÑ Á×À½À» ÃÊ·¡ÇÑ´Ù. »óÇǼºÀΠ°ÍÀ» ¾ÏÁ¾À̶ó Çϰí, ºñ»óÇǼºÀΠ°ÍÀ» À°Á¾À̶ó ÇÑ´Ù.
¿µ¹® malignant melanoma ÇÑ±Û ¾Ç¼ºÈæ»öÁ¾
¼³¸í   
  ÇǺο¡¼­ »ý±â´Â ¾ÏÀÇ ÀÏÁ¾. ÁַΠ¹éÀο¡°Ô È£¹ßÇϸç, 50´ë~70´ë¿¡ ¸¹ÀÌ ¹ß»ýÇϰí, ÀþÀº ¿©¼º¿¡°Ô Áõ°¡Çϴ °æÇâÀÌ ÀÖÀ¸¸ç, ÇǺξÏÁß 1~3%¸¦ Â÷ÁöÇϴ µå¹® º´À¸·Î ÇǺο͠±âŸ ±â°üÀÇ ¸á¶ó´Ñ ¼¼Æ÷°è¿¡¼­ À¯·¡Çϴ ¾Ç¼ºÁ¾¾çÀÌ´Ù.
  
  ¿øÀÎÀ¸·Î Àϱ¤³ëÃâ°ú Á÷Á¢ÀûÀΠ°ü°è°¡ ÀÖÀ¸¸ç °¡Á·Àû ¹ß»ýµµ º¼ ¼ö ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • quality specification
    ǰÁú±Ô°Ý
  • specification
    1. ¸í¼¼ 2. ±Ô°Ý 3. ¸í¼¼¼­, ½Ã¹æ¼­
  • benign neoplasm
    ¾ç¼ºÁ¾¾ç
  • cutaneous neoplasm
    ÇǺÎÁ¾¾ç
  • cystic neoplasm
    ³¶¼º½Å»ý¹°, ³¶¼ºÁ¾¾ç
  • neoplasm
    ½Å»ý¹°, Á¾¾ç
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • binding site
    °áÇÕºÎÀ§
  • combining site
    °áÇÕºÎÀ§
  • donor site
    Á¦°øºÎÀ§, °ø¿©ºÎÀ§
  • fragile site
    Ãë¾àºÎÀ§
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • specification
    Àü¹®È­, ¼±º°È­
  • neoplasm
    ½Å»ý¹°, Á¾¾ç
  • cystic neoplasm
    ³¶Á¾
  • site
    ºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§
  • malignant
    ¾Ç¼º-
  • malignant mesothelioma
    ¾Ç¼ºÁßÇÇÁ¾
  • malignant melanoma
    ¾Ç¼ºÈæ»öÁ¾
  • neuroleptic malignant syndrome
    Ç×Á¤½Åº´¾à¹°¾Ç¼ºÁõÈıº
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • malignant transformation
    ¾Ç¼º¼¼Æ÷Àüȯ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • borderline malignant epithelial ovarian neoplasm
    °æ°è¾Ç¼º»óÇdz­¼ÒÁ¾¾ç
  • quality specification
    ǰÁú±Ô°Ý
  • specification
    Àü¹®È­, ¼±º°È­
  • cutaneous neoplasm
    ÇǺÎÁ¾¾ç
  • neoplasm
    ½Å»ý¹°, Á¾¾ç
  • absorption site
    Èí¼öºÎÀ§
  • acceptor site
    ¼ö¿ëºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • binding site
    °áÇÕºÎÀ§
  • combining site
    °áÇÕºÎÀ§
  • definitive site
    Âø»óºÎÀ§
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hepatic neoplasm
    °£½Å»ý¹°(ÊÜãæßæÚª).
  • quality specification
    ǰÁú±Ô°Ý(̰̤˻˭).
  • Hodgkin s disease =malignant lymphoma
    È£ÁîŲº´.
  • Hodgkin s disease =malignant lymphoma
    È£ÁîŲº´.
  • granuloma, malignant
    ¾Ç¼ºÀ°¾ÆÁ¾
  • histiocytoma,malignant fibrous
    Á¶Á÷±¸Á¾, ¾Ç¼º ¼¶À¯¼º
  • histiocytosis,malignant
    ¾Ç¼º
  • hypertension,malignant
    ¾Ç¼º(äÂàõ)
  • absorption site
    Èí¼öÁ¡
  • acceptor site
    ¼ö¿ëºÎÀ§
  • active site
    Ȱ¼ºÀÚ¸®.
  • antibody binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody combining site
    Ç×ü°áÇÕºÎ(ù÷ô÷Ì¿ùêÝ»).
  • antigen binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen combining site
    Ç׿ø°áÇպΠ(¡­Ì¿ùêÝ»).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lysis from without
    ÆÄÁö¼º ¿ÜÀοë±Õ
  • malignant neoplasm
    ¾Ç¼º½Å»ý¹°(¡­ãæßæÚª).
  • malignant neoplasm
    ¾Ç¼º½Å»ý¹°(¡­ãæßæÚª)
  • quality specification
    ǰÁú±Ô°Ý(̰̤˻˭).
  • specification
    Àü¹®È­(ËøËÑÌ´).[Ä¡°ú]±Ô°Ý(˻˭).
  • specification
    Àü¹®È­(îöÚ¦ûù).[Ä¡°ú]±Ô°Ý(Ю̫).
  • trichromatic specification
    »ï»ö±â¹ý(¡­ÑÀÛö).
  • cutaneous neoplasm
    ÇǺνŻý¹°, ÇǺÎÁ¾¾ç(¡­ðþåË).
  • cutaneous neoplasm
    ÇǺνŻý¹°, ÇǺÎÁ¾¾ç(¡­ðþåË)
  • hepatic neoplasm
    °£½Å»ý¹°(ÊÜãæßæÚª).
  • lymphoplasmacytic neoplasm
    ¸²ÇÁÇüÁú¼¼Æ÷¼º ½Å»ý¹°
  • neoplasm =neoplasma
    ½Å»ý¹° Á¾¾ç(¡­ðþåË)
  • organoid neoplasm
    ±â°ü¾ç½Å»ý¹°(ÐïίåÆãæßæÚª)
  • testis neoplasm
    °íȯ½Å»ý¹°(ÍÂü¯ãæßæÚª).
  • testis neoplasm
    °íȯ½Å»ý¹°(ÍÂü¯ãæßæÚª)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Variations of site
    À§Ä¡º¯ÀÌ
    [¿¾ ¿ë¾î] À§Ä¡ÀÌ»ó
  • Corporal site
    ÀڱøöÅëÀÓ½Å
    [¿¾ ¿ë¾î] ÀÚ±ÃüºÎ
  • Absorption site
    Èí¼öÁ¡
    [¿¾ ¿ë¾î] Èí¼öÃÊÁ¡
  • Fundic site
    ÀڱùٴÚÀÓ½Å
    [¿¾ ¿ë¾î] ÀÚ±ÃÀúºÎ
  • Definitive site
    Âø»óÀÚ¸®
    [¿¾ ¿ë¾î] À§Ä¡¼±Á¤
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • A-site-P-site moel
    AÀÚ¸® PÀÚ¸® ¸ðµ¨
  • acceptor site
    ¼ö¿ëºÎÀ§ (â¥é»Ý»êÈ)
  • active site
    Ȱ¼º(üÀàõ)ÀÚ¸®
  • active site-directed irreversible inhibitor
    Ȱ¼º(üÀàõ)ÀÚ¸®ÁöÇâÀû ºÒ°¡¿ªÀúÇØÁ¦(ò¦ú¾îÜÝÕʦæ½îÁúªð¥)
  • alternate-site model
    ±³´ëºÎÀ§(ÎßÓÛÝ»êÈ)¸ðÅÚ
  • amino acid attachement site
    ¾Æ¹Ì³ë»ê(ß«) ºÎÂø(ݾó·)ÀÚ¸®
  • aminoacyl site
    ¾Æ¹Ì³ë¾Æ½Ç ÀÚ¸®
  • aminoacyl-tRNA site
    ¾Æ¹Ì³ë¾Æ½ÇtRNA ÀÚ¸®
  • antibody combining site
    Ç×ü°áÂø(ù÷ô÷Ì¿ó·)ÀÚ¸®
  • antigen binding site
    Ç׿ø°áÇÕ(ù÷ê«Ì¿ùê)ÀÚ¸®
  • AP site
    AP ÀÚ¸®
  • A-site
    AÀÚ¸®
  • attachment site
    ºÎÂø(ݾó·)ÀÚ¸®
  • binding site
    °áÇÕ(Ì¿ùê)ÀÚ¸®
  • catalytic site
    Ã˸Å(õºØÚ)ÀÚ¸®
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • malignant neoplasm
    ¾Ç¼º½Å»ý¹°
  • neoplasm
    ½Å»ý¹°
  • site
    À§Ä¡,»çÀÌÆ®
  • web site
    À¥½ÎÀÌÆ®
  • malignant
    ¾Ç¼ºÀÇ
  • malignant adenoma
    ¾Ç¼º¼±Á¾
  • malignant cachexia
    ¾Ç¼º¾Ç¾×Áú
  • malignant change
    ¾Ç¼ºº¯È­
  • malignant degeneration
    ¾Ç¼ºÈ­
  • malignant granuloma
    ¾Ç¼ºÀ°¾ÆÁ¾
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾ÐÁõ
  • malignant polyp
    ¾Ç¼ºÆú¸³
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MH malignant histiocytosis; malignant hyperpyrexia; malignant hypertension; malignant hyperthermia; mam...
MHS major histocompatibility system; malignant hyperthermia in swine; malignant hyperthermia syndrome; m...
FS factor of safety; Fanconi syndrome; Felty syndrome; fibromyalgia syndrome; field stimulation; Fisher...
FMN first malignant neoplasm; flavin mononucleotide; frontomaxillonasal [suture]
MRN malignant renal neoplasm
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SMN Second Malignant Neoplasm
FFWO Fusion-from-without
SCIWORA Spinal Cord Injury Without Radiographic Abnormality
Site 1 site
CMM Cutaneous malignant melanoma
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • C80
    Malignant neoplasm without specification of site
    ºÎÀ§ÀÇ ¸í½Ã°¡ ¾ø´Â ¾Ç¼º½Å»ý¹°
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • disseminated malignant neoplasm
    ÆÛÁ® ÀÖ´Â ¾Ï
  • malignant neoplasm
    ¾Ç¼º ½Å»ý¹°
  • disk displacement without reduction
    ºñÁ¤º¹¼º °üÀý¿øÆÇ º¯À§
  • KDA Specification
    ´ëÇÑÄ¡°úÀÇ»çÇùȸ ±Ô°Ý
  • migraine without aura
    ºñÀüÁ¶Çü ÆíµÎÅë, Àü±¸ Áõ»ó ¾ø´Â ÆíµÎÅë, Àü±¸ Áõ»óÀÌ ¾ø´Â ÆíµÎÅë
    µ¿ÀǾî=common migraine. ±¹¼ÒÀûÀÎ ½Å°æ Àå¾Ö°¡ µÎÅëÀ» À¯¹ßÇÏÁö´Â ¾ÊÁö¸¸ ÀüÁ¶Çü ÆíµÎÅëÀÇ ´Ù¸¥ ¸ðµç Ư¼ºÀº µ¿ÀÏÇÏ´Ù.
  • specification
    Àü¹®È­, ±Ô°Ý
    Ä¡°ú¿ë Àç·á¿¡ ÇÊ¿äÇÑ Á¶¼º ¹× ¼ºÁú¿¡ ´ëÇÏ¿© ¼¼¹ÐÈ÷ Ç¥±âÇÑ Ç¥ÁØ ¶Ç´Â ¼öÁØÀ» °¡¸®Å²´Ù.
  • hematologic neoplasm
    Ç÷¾× ½Å»ý¹°
  • immunologic neoplasm
    ¸é¿ªÇÐÀû ½Å»ý¹°, ¸é¿ªÇÐÀû Á¾¾ç
  • antigen binding site
    Ç׿ø °áÇÕ ºÎÀ§
    ¸é¿ª ±Û·ÎºÒ¸°ÀÇ 3Â÷ ±¸Á¶»ó H ¼â¿Í L ¼âÀÇ °¡º¯¿µ¿ª¿¡¼­ ±¸¼ºµÇ¾î ÀÖ´Â Ç׿ø°ú °áÇÕÇÏ´Â ºÎÀ§.
  • antigen combining site
    Ç׿ø °áÇÕºÎ
  • antigen recognition site
    Ç׿ø ½Äº°ºÎ
  • cleavage site
    ºÐ¿­ ºÎÀ§
  • combining site
    °áÇÕºÎ
  • electrophilic site
    Ä£ÀüÀÚ ¹ÝÀÀ¹°
  • molecular site
    ºÐÀÚ À§
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
migraine without headache A classic migraine episode in which the teichopsia is not followed by a headache.
Synonym: migraine without headache.
(05 Mar 2000)
without Unless; except; introducing a clause. "You will never live to my age without you keep yourselves in breath with exercise, and in heart with joyfulness." (Sir P. Sidney)
Now rarely used by good writers or speakers.
Source: Websters Dictionary
(01 Mar 1998)
subluxation without erosion <radiology> Systemic lupus erythematosis, Jaccoud's
(12 Dec 1998)
antibodies, neoplasm Immunoglobulins induced by antigens specific for tumours other than the normally occurring histocompatibility antigens.
(12 Dec 1998)
antigens, neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumour cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
(12 Dec 1998)
brain neoplasm Neoplasms of the part of the central nervous system contained within the cranium.
(12 Dec 1998)
genes, structural, neoplasm DNA sequences that code for RNA and for the proteins required for the enzymatic and structural function of neoplastic cells.
(12 Dec 1998)
mucinous cystic neoplasm of pancreas <radiology> = macrocystic adenoma of pancreas, cystadenoma / cystadenocarcinoma, M:F = 1:9, 40-60 years of age, malignant or pre-malignant, large mass (mean 12 cm), multilocular cysts, thick septations, tail / body in 85% (unlike adenocarcinoma and microcystic adenoma), hypo-/avascular, Differential diagnosis: panc pseudocyst, ** Cf: microcystic adenoma
(12 Dec 1998)
histoid neoplasm Old term for a neoplasm characterised by a cytohistologic pattern that closely resembles the tissue from which the neoplastic cells are derived.
(05 Mar 2000)
neoplasm <oncology, pathology> New and abnormal growth of tissue, which may be benign or cancerous.
(16 Dec 1997)
neoplasm circulating cells Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumours.
(12 Dec 1998)
neoplasm: gallium imaging <radiology> Useful: Hodgkin disease and histiocytic form of NHL poor sensitivity below the diaphragm, Burkitt lymphoma: almost 100% sensitivity, hepatoma: 90% sensitivity, melanoma: 90% sensitivity, leukaemia possibly useful: NHL: good for large and mediastinal lesions, nodal metastases from seminoma and embryonal cell carcinoma: 87% sensitivity, non-small cell lung CA: 85% sensitive not useful: head and neck, GI (especially adenocarcinoma), breast, gynaecological, kiddie tumours see: gallium: indications
(12 Dec 1998)
neoplasm invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
(12 Dec 1998)
neoplasm metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. The ability to metastasize is characteristic of all malignant neoplasms.
(12 Dec 1998)
neoplasm recurrence, local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neoplasm
    (º´¸®)ü³»¿¡ »ý±â´Â ½Å»ý¹°;(ƯÈ÷)Á¾¾ç
  • specification
    »ó¼ú
  • specification
    »ó¼úÇÔ;¸í¼¼¼­;¸í¼¼;³»¿ª
  • malignant
    ¾ÇÀǸ¦ ǰÀº; ¾Ç¼ºÀÇ; ¹ÝÇ×ÀÚ
  • malignant
    À¯ÇØÇÑ;¾Ç¼ºÀÇ;¾ÇÀǸ¦ ǰÀº;... (¿µ»ç) Charles I ½Ã´ëÀÇ ¿Õ´ç¿ø
  • malignant melanoma
    ¾Ç¼º Èæ»öÁ¾
  • go without
    -ÀÌ ¾ø´Ù; ¾øÀÌ Áö³»´Ù
  • without
    ~ÇÏÁö ¾Ê°í,~¾øÀÌ
  • without fail
    ¾î±è¾øÀÌ
  • without
    ¿ÜºÎ¿¡;Áý¹Û¿¡;...¾øÀÌ
  • without
    ...ÇÏÁö ¾Ê°í¼­´Â
  • without
    ...¾øÀÌ;...ÇÏÁö ¾Ê°í;...ÀÌ ¾øÀ¸¸é;...ÀÇ ¹Û¿¡;do(go)~ ...¾øÀÌ ¶§¿ì´Ù;~ day ¹«±âÇÑÀ¸·Î
  • without
    ~ leave ¹«´ÜÈ÷;~ reserve »ç¾ç ¾Ê°í
  • site
    À§Ä¡
  • caravan park (site)
    À̵¿ÁÖÅÃ(Æ®·¹ÀÏ·¯) ÁÖÂ÷Àå
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á